Immunology Live – 10 feb. 2016. The FDA recently recommended approval for a biosimilar rheumatoid arthritis drug that could save patients billions over time. The drug, called Remsima, is a biosimilar to Remicade. The FDA will take the panel’s advice into consideration and will approve or reject the drug by early April 2016.
